This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/pharmgkb/
n26http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n30http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/drugbank/
n28http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/patent/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n29http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00583/identifier/wikipedia/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00583
rdf:type
n3:Drug
n3:description
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
n3:dosage
n12:271B4E72-363D-11E5-9242-09173F13E4C5 n12:271B4E73-363D-11E5-9242-09173F13E4C5 n12:271B4E74-363D-11E5-9242-09173F13E4C5 n12:271B4E75-363D-11E5-9242-09173F13E4C5 n12:271B4E76-363D-11E5-9242-09173F13E4C5 n12:271B4E77-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Olpin SE: Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. Clin Lab. 2005;51(5-6):289-306. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15991803 # Steiber A, Kerner J, Hoppel CL: Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2004 Oct-Dec;25(5-6):455-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15363636
n3:group
approved
n3:halfLife
17.4 hours (elimination) following a single intravenous dose.
n3:indication
For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.
n3:manufacturer
n16:271B4E66-363D-11E5-9242-09173F13E4C5 n16:271B4E64-363D-11E5-9242-09173F13E4C5 n16:271B4E65-363D-11E5-9242-09173F13E4C5 n16:271B4E6A-363D-11E5-9242-09173F13E4C5 n16:271B4E68-363D-11E5-9242-09173F13E4C5 n16:271B4E69-363D-11E5-9242-09173F13E4C5 n16:271B4E67-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00583 n28:DB00583
dcterms:title
L-Carnitine
adms:identifier
n10:L-Carnitine n11:PA450154 n17:10917 n18:D02176 n19:0517-1055-25 n20:46505864 n21:16347 n22:C00318 n23:10455 n24:DB00583
n3:mechanismOfAction
Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases.
n3:packager
n16:271B4E62-363D-11E5-9242-09173F13E4C5 n16:271B4E63-363D-11E5-9242-09173F13E4C5 n16:271B4E60-363D-11E5-9242-09173F13E4C5 n16:271B4E61-363D-11E5-9242-09173F13E4C5
n3:patent
n15:6335369
n3:routeOfElimination
Following a single intravenous dose, 73.1 +/- 16% of the dose was excreted in the urine during the 0-24 hour interval. Post administration of oral carnitine supplements, in addition to a high carnitine diet, 58-65% of the administered radioactive dose was recovered from urine and feces in 5-11 days.
n3:synonym
Vitamin bt (R)-Carnitine Levocarnitina (-)-L-Carnitine (S)-Carnitine L-Carnitine Levocarnitin 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt Carnicor Karnitin Carnitine Levocarnitinum Lévocarnitine (-)-L-Carnitin Carnitor (-)-Carnitine Carnitene
n3:toxicity
LD<sub>50</sub> > 8g/kg (mouse, oral). Adverse effects include hypertension, fever, tachycardia and seizures.
n3:volumeOfDistribution
The steady state volume of distribution (Vss) of an intravenously administered dose, above endogenous baseline levels, was calculated to be 29.0 +/- 7.1L. However this value is predicted to be an underestimate of the true Vss.
n13:hasAHFSCode
n14:40-20-00
n3:mixture
n27:271B4E5E-363D-11E5-9242-09173F13E4C5 n27:271B4E5F-363D-11E5-9242-09173F13E4C5 n27:271B4E5D-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
None
n3:salt
n3:synthesisReference
Noguchi, J. and Sakota, N.; US. Patent 3,135,788; June 2,1964; assigned to Nihon Zoki Seiyaku Kabushikikaisha (Japan).
n29:hasConcept
n30:M0003493
foaf:page
n26:carnitor.htm
n3:IUPAC-Name
n4:271B4E7C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4E82-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4E81-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4E7E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4E7F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4E80-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4E92-363D-11E5-9242-09173F13E4C5 n4:271B4E7A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4E7B-363D-11E5-9242-09173F13E4C5 n4:271B4E78-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4E79-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4E94-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4E88-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4E89-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4E83-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4E84-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4E86-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4E85-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4E87-363D-11E5-9242-09173F13E4C5
n3:absorption
Absolute bioavailability is 15% (tablets or solution). Time to maximum plasma concentration was found to be 3.3 hours.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
541-15-1
n3:category
n3:clearance
Total body clearance was found to be a mean of 4L/h.
n3:containedIn
n7:271B4E6F-363D-11E5-9242-09173F13E4C5 n7:271B4E70-363D-11E5-9242-09173F13E4C5 n7:271B4E6E-363D-11E5-9242-09173F13E4C5 n7:271B4E6D-363D-11E5-9242-09173F13E4C5 n7:271B4E71-363D-11E5-9242-09173F13E4C5 n7:271B4E6B-363D-11E5-9242-09173F13E4C5 n7:271B4E6C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4E8E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4E90-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4E91-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4E93-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4E8D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4E8C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4E8F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4E7D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4E8A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4E8B-363D-11E5-9242-09173F13E4C5